Abstract
Objective To analyze genetically based impairment in histamine-metabolising enzymes in patients with Parkinson’s disease (PD). Methods Leukocytary DNA from 214 PD patients and a control group of 295 unrelated healthy individuals was studied for nonsynonymous histamine N-methyltransferase (HNMT) and diamine oxidase (ABP1) polymorphisms by using amplification–restriction analyses. Results An association of the HNMT Thr105Ile polymorphism, but not of the ABP1 His645Asp polymorphism, with PD was observed. Patients with PD showed a higher frequency of homozygous HNMT genotypes leading to high activity with a gene-dose effect (P < 0.001), as compared to healthy subjects. These findings were independent of gender, but the association with the HNMT polymorphism is higher among patients with late-onset PD (P < 0.0001). Conclusion These results, combined with previous findings indicating alterations in histamine levels in patients with PD, suggest that alterations of histamine homeostasis in the SNC are associated with the risk for PD.
Similar content being viewed by others
References
Abbas, N., Lucking, C. B., Ricard, S., Durr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J. R., Gasser, T., Marconi, R., Broussolle, E., Brefel-Courbon, C., Harhangi, B. S., Oostra, B. A., Fabrizio, E., Bohme, G. A., Pradier, L., Wood, N. W., Filla, A., Meco, G., Denefle, P., Agid, Y., & Brice, A. (1999). A wide variety of mutations in the parkin gene are responsible for autosomal recessive Parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. Human Molecular Genetics, 8, 567–574.
Abeliovich, A., & Flint Beal, M. (2006). Parkinsonism genes: Culprits and clues. Journal of Neurochemistry, 99, 1062–1072.
Agundez, J. A., Jimenez-Jimenez, F. J., Luengo, A., Bernal, M. L., Molina, J. A., Ayuso, L., Vazquez, A., Parra, J., Duarte, J., Coria F., et al. (1995). Association between the oxidative polymorphism and early onset of Parkinson’s disease. Clinical Pharmacology and Therapeutics, 57, 291–298.
Agundez, J. A., Jimenez-Jimenez F. J., Luengo A., Molina J. A., Orti-Pareja M., Vazquez A., Ramos F., Duarte J., Coria F., Ladero J. M., Alvarez-Cermeno J. C., & Benitez J. (1998). Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson’s disease. Neurology, 51, 1587–1592.
Agundez, J. A., Rodriguez I., Olivera M., Ladero J. M., Garcia M. A., Ribera J. M., & Benitez J. (1997). CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing, 26, 147–151.
Anichtchik, O. V., Rinne, J. O., Kalimo, H., & Panula, P. (2000). An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Experimental Neurology, 163, 20–30.
Ayuso, P., Garcia-Martin, E., Martinez, C., & Agundez, J. A. (2007). Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenet Genomics, 17, 687–693.
Bonifati, V., Fabrizio, E., Vanacore, N., De Mari, M., & Meco, G. (1995). Familial Parkinson’s disease: A clinical genetic analysis. The Canadian Journal of Neurological Sciences, 22, 272–279.
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N., van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M., Oostra, B. A., & Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299, 256–259.
Brennan, P. (2002). Gene–environment interaction and aetiology of cancer: What does it mean and how can we measure it? Carcinogenesis, 23, 381–387.
Chade, A. R., Kasten, M., & Tanner, C. M. (2006). Nongenetic causes of Parkinson’s disease. Journal of Neural Transmission, Suppl, 147–151.
Chan, D. K., Lam, M. K., Wong, R., Hung, W. T., & Wilcken, D. E. (2003). Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology, 60, 1002–1005.
Clarimon, J., Scholz, S., Fung, H. C., Hardy, J., Eerola, J., Hellstrom, O., Chen, C. M., Wu, Y. R., Tienari, P. J., & Singleton, A. (2006). Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. American Journal of Human Genetics, 78, 1082–1084; author reply 1092–1094.
Coelho, M. H., Silva, I. J., Azevedo, M. S., & Manso, C. F. (1991). Decrease in blood histamine in drug-treated parkinsonian patients. Molecular and Chemical Neuropathology, 14, 77–85.
Daly, A. K., & Day, C. P. (2001). Candidate gene case–control association studies: Advantages and potential pitfalls. British Journal of Clinical Pharmacology, 52, 489–499.
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997). Prevalence of Parkinsonism and Parkinson’s disease in Europe: The EUROPARKINSON Collaborative Study. European community concerted action on the epidemiology of Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 62, 10–15.
Dekker, M. C., Bonifati, V., & van Duijn C. M. (2003). Parkinson’s disease: Piecing together a genetic jigsaw. Brain, 126, 1722–1733.
Elbaz, A., Grigoletto, F., Baldereschi, M., Breteler, M. M., Manubens-Bertran, J. M., Lopez-Pousa, S., Dartigues, J. F., Alperovitch, A., Tzourio, C., & Rocca, W. A. (1999). Familial aggregation of Parkinson’s disease: A population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology, 52, 1876–1882.
Elbaz, A., Nelson, L. M., Payami, H., Ioannidis, J. P., Fiske, B. K., Annesi, G., Carmine Belin, A., Factor, S. A., Ferrarese, C., Hadjigeorgiou, G. M., Higgins, D. S., Kawakami, H., Kruger, R., Marder, K. S., Mayeux, R. P., Mellick, G. D., Nutt, J. G., Ritz, B., Samii, A., Tanner, C. M., Van Broeckhoven, C., Van Den Eeden S. K., Wirdefeldt, K., Zabetian, C. P., Dehem, M., Montimurro, J. S., Southwick, A., Myers, R. M., & Trikalinos, T. A. (2006). Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson’s disease: A large-scale international study. Lancet Neurology, 5, 917–923.
Farrer, M. J., Haugarvoll, K., Ross, O. A., Stone, J. T., Milkovic, N. M., Cobb, S. A., Whittle, A. J., Lincoln, S. J., Hulihan, M. M., Heckman, M. G., White, L. R., Aasly, J. O., Gibson, J. M., Gosal, D., Lynch, T., Wszolek, Z. K., Uitti, R. J., & Toft, M. (2006). Genomewide association, Parkinson disease, and PARK10. American Journal of Human Genetics, 78, 1084–1088; author reply 1092–1094.
Fearnley, J. M., & Lees, A. J. (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain, 114(Pt 5), 2283–2301.
Funayama, M., Hasegawa K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology, 51, 296–301.
Gasser, T., Muller-Myhsok, B., Wszolek, Z. K., Oehlmann, R., Calne, D. B., Bonifati, V., Bereznai, B., Fabrizio, E., Vieregge, P., & Horstmann, R. D. (1998). A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nature Genetics, 18, 262–265.
Gibb, W. R., & Lees, A. J. (1989). Prevalence of Lewy bodies in Alzheimer’s disease. Annals of Neurology, 26, 691–693.
Goris, A., Williams-Gray, C. H., Foltynie, T., Compston, D. A., Barker, R. A., & Sawcer, S. J. (2006). No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. American Journal of Human Genetics, 78, 1088–1090; author reply 1092–1094.
Hampshire, D. J., Roberts, E., Crow, Y., Bond, J., Mubaidin, A., Wriekat, A. L., Al-Din, A., & Woods, C. G. (2001). Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. Journal of Medical Genetics, 38, 680–682.
Hardy, J., Cai, H., Cookson, M. R., Gwinn-Hardy, K., & Singleton, A. (2006). Genetics of Parkinson’s disease and parkinsonism. Annals of Neurology, 60, 389–398.
Hicks, A. A., Petursson, H., Jonsson, T., Stefansson, H., Johannsdottir, H. S., Sainz, J., Frigge, M. L., Kong, A., Gulcher, J. R., Stefansson, K., & Sveinbjornsdottir, S. (2002). A susceptibility gene for late-onset idiopathic Parkinson’s disease. Annals of Neurology, 52, 549–555.
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry, 55, 181–184.
Jimenez-Jimenez, F. J., Tabernero, C., Mena, M. A., Garcia de Yebenes, J., Garcia de Yebenes, M. J., Casarejos, M. J., Pardo, B., Garcia-Agundez, J. A., Benitez, J., Martinez, A., et al. (1991). Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. Journal Neurochemistry, 57, 81–87.
Kim, S. H., Krapfenbauer, K., Cheon, M. S., Fountoulakis, M., Cairns, N. J., & Lubec, G. (2002). Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick’s disease. Neuroscience Letters, 321, 169–172.
Langlais, P. J., Zhang, S. X., Weilersbacher, G., Hough, L. B., & Barke, K. E. (1994). Histamine-mediated neuronal death in a rat model of Wernicke’s encephalopathy. Journal of Neuroscience Research, 38, 565–574.
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P. J., Wilkinson, K. D., & Polymeropoulos, M. H. (1998). The ubiquitin pathway in Parkinson’s disease. Nature, 395, 451–452.
Li, Y., Rowland, C., Schrodi, S., Laird, W., Tacey, K., Ross, D., Leong, D., Catanese, J., Sninsky, J., & Grupe, A. (2006). A case-control association study of the 12 single-nucleotide polymorphisms implicated in Parkinson disease by a recent genome scan. American Journal of Human Genetics, 78, 1090–1092; author reply 1092–1094.
Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., Pant, P. V., Frazer, K. A., Cox, D. R., & Ballinger, D. G. (2005). High-resolution whole-genome association study of Parkinson disease. American Journal of Human Genetics, 77, 685–693.
Marder, K., Tang, M. X., Mejia, H., Alfaro, B., Cote, L., Louis, E., Groves, J., & Mayeux, R. (1996). Risk of Parkinson’s disease among first-degree relatives: A community-based study. Neurology, 47, 155–160.
Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., Sanpei, K., Koike, R., Mori, H., Kondo, T., Mizutani, Y., Schaffer, A. A., Yamamura, Y., Nakamura, S., Kuzuhara, S., Tsuji, S., & Mizuno, Y. (1997). Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2–27. American Journal of Human Genetics, 60, 588–596.
Obata, T. (2002). Semicarbazide-sensitive amine oxidase (SSAO) in the brain. Neurochemical Research, 27, 263–268.
Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Rudolph, A., Shults, C., Conneally, P. M., & Foroud, T. (2003). Significant linkage of Parkinson disease to chromosome 2q36–37. American Journal of Human Genetics, 72, 1053–1057.
Panula, P., Yang, H. Y., & Costa, E. (1984). Histamine-containing neurons in the rat hypothalamus. Proceedings of the National Academy of Sciences of the United States of America, 81, 2572–2576.
Pértegas Díazs, S., & Pita Fernández, S. (2003). Cálculo del poder estadístico de un estudio. Cad Aten Prim, 10, 59–63.
Piccini, P., Burn, D. J., Ceravolo, R., Maraganore, D., & Brooks, D. J. (1999). The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 45, 577–582.
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di, Iorio, G., Golbe, L. I., & Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 276, 2045–2047.
Prell, G. D., & Green, J. P. (1991). Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Supplement, 33, 343–363.
Preuss, C. V., Wood, T. C., Szumlanski, C. L., Raftogianis, R. B., Otterness, D. M., Girard, B., Scott, M. C., & Weinshilboum, R. M. (1998). Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Molecular Pharmacology, 53, 708–717.
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., & Gwinn-Hardy, K. (2003). Alpha-Synuclein locus triplication causes Parkinson’s disease. Science, 302, 841.
Tan, E. K., Chan, D. K., Ng, P. W., Woo, J., Teo, Y. Y., Tang, K., Wong, L. P., Chong, S. S., Tan, C., Shen, H., Zhao, Y., & Lee, C. G. (2005). Effect of MDR1 haplotype on risk of Parkinson disease. Archives of Neurology, 62, 460–464.
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999). Parkinson disease in twins: an etiologic study. The Journal of American Medical Association, 281, 341–346.
Thoburn, K. K., Hough, L. B., Nalwalk, J. W., & Mischler, S. A. (1994). Histamine-induced modulation of nociceptive responses. Pain, 58, 29–37.
Thomas, B., & Prell, G. D. (1995). Imidazoleacetic acid, a gamma-aminobutyric acid receptor agonist, can be formed in rat brain by oxidation of histamine. Journal of Neurochemisry, 65, 818–826.
Valente, E. M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A. E., Caputo, V., Romito, L., Albanese, A., Dallapiccola, B., & Bentivoglio, A. R. (2004). PINK1 mutations are associated with sporadic early-onset parkinsonism. Annals of Neurology, 56, 336–341.
van Duijn, C. M., Dekker, M. C., Bonifati, V., Galjaard, R. J., Houwing-Duistermaat, J. J., Snijders, P. J., Testers, L., Breedveld, G. J., Horstink, M., Sandkuijl, L. A., van Swieten, J. C., Oostra, B. A., & Heutink, P. (2001). Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. American Journal of Human Genetics, 69 , 629–634.
Vizuete, M. L., Merino, M., Venero, J. L., Santiago, M., Cano, J., & Machado, A. (2000). Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. Journal of Neurochemistry, 75, 540–552.
Watanabe, T., Taguchi, Y., Shiosaka, S., Tanaka, J., Kubota, H., Terano, Y., Tohyama, M., & Wada, H. (1984). Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Research, 295, 13–25.
Wilk, J. B., Tobin, J. E., Suchowersky, O., Shill, H. A., Klein, C., Wooten, G. F., Lew, M. F., Mark, M. H., Guttman, M., Watts, R. L., Singer, C., Growdon, J. H., Latourelle, J. C., Saint-Hilaire, M. H., DeStefano, A. L., Prakash, R., Williamson, S., Berg, C. J., Sun, M., Goldwurm, S., Pezzoli, G., Racette, B. A., Perlmutter, J. S., Parsian, A., Baker, K. B., Giroux, M. L., Litvan, I., Pramstaller, P. P., Nicholson, G., Burn, D. J., Chinnery, P. F., Vieregge, P., Slevin, J. T., Cambi, F., MacDonald, M. E., Gusella, J. F., Myers, R. H., & Golbe, L. I. (2006). Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology, 67, 2206–2210.
Acknowledgements
This work was supported in part by Grants SAF 2003–00967 from Ministerio de Ciencia y Tecnología, FIS 05/1056 and 06/1252 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agúndez, J.A.G., Luengo, A., Herráez, O. et al. Nonsynonymous Polymorphisms of Histamine-Metabolising Enzymes in Patients with Parkinson’s Disease. Neuromol Med 10, 10–16 (2008). https://doi.org/10.1007/s12017-007-8017-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-007-8017-7